Is NMN Safe for Long-Term Use? What the Studies Show

The honest answer has two halves. In human trials, NMN has been well tolerated at daily doses up to 1,250 mg, with no serious safety signals reported [1][5]. But the longest of those trials ran 12 weeks [2]. Nobody has published a study of people taking NMN for years, which is exactly how most people actually use it.

There is also a second answer that most articles on this topic skip entirely. As of a notice dated 24 July 2026, NMN is not an approved supplement ingredient in India [3].

This information is for educational purposes only. It is not medical advice. Talk to a healthcare professional before starting any new supplement.

What the NMN Safety Studies Actually Measured

NMN is a precursor to NAD+, a coenzyme that more than 400 enzymes in the body need to work [4]. NAD+ levels fall with age, and the idea behind NMN is to top them back up.

Four human trials carry most of the weight on safety.

A randomised, double-blind, placebo-controlled trial of 80 healthy middle-aged adults tested 300 mg, 600 mg, and 900 mg daily against placebo for 60 days. All 80 participants finished. The researchers reported no safety issues from adverse event monitoring, laboratory measures, or clinical measures [1].

A second randomised, double-blind, placebo-controlled trial ran 12 weeks in 36 healthy middle-aged adults, with participants taking 125 mg twice a day. It was well tolerated and produced no adverse events [2].

A third study pushed the dose higher. It gave 1,250 mg once daily to 31 healthy adults aged 20 to 65 for four weeks and found no changes beyond normal physiological variation across blood work, urine analysis, and body composition. No severe adverse events occurred [5].

The fourth was an eight-week study in 11 middle-aged Japanese men taking 250 mg daily. It was well tolerated, though it was single-arm and open-label, meaning there was no placebo group and everyone knew what they were taking [6].

The Duration Ceiling: Why "Long-Term" Is Doing a Lot of Work

Read those four studies together and a pattern shows up that matters more than any individual result.

The longest one ran 12 weeks.

Several of these trials use the phrase "long-term" in their titles. In supplement research, that phrase means something narrower than most readers assume. It signals repeated daily dosing rather than a one-off dose, and nothing about years.

Twelve weeks is long-term compared to one tablet. It is not long-term compared to a supplement someone starts in their forties and keeps taking indefinitely.

This is a gap in the evidence, not a finding of harm. Nothing in the published record suggests NMN becomes dangerous at month four. The point is narrower and more useful: no one has looked.

A 2023 review in Advances in Nutrition covering the human trials to date reached a similar position, noting that most evidence for NMN comes from cell and animal models and that questions remain about safety and physiological effects in humans [7].

Grading the Evidence: Three Things Worth Knowing

Sample sizes are small. The four safety trials above enrolled 80, 36, 31, and 11 people. For comparison, drug safety trials routinely enrol thousands. Small trials can detect common side effects. They are underpowered to catch rare ones.

Several trials carry industry ties. In the 80-person dose-ranging trial, the authors disclosed that one is an employee of Abinopharm and two are employees of Aba Chemicals [1]. Disclosure is the correct practice and its presence is a mark of transparency, not a reason to discard the data. It is still context a reader deserves.

Participants were healthy to begin with. These trials recruited healthy adults. That tells you little about how NMN behaves in someone on multiple medications, or someone with kidney or liver impairment.

What Is Known About NMN Side Effects

Across the human trials, reported side effects have been mild, with gastrointestinal complaints most common. The trials above reported no serious adverse events.

NMN's chemical family gives some additional context. NMN converts to nicotinamide in the body, and nicotinamide is a form of niacin, vitamin B3. According to the NIH Office of Dietary Supplements, nicotinic acid and nicotinamide have different toxicity profiles, and this distinction matters [4].

Nicotinic acid causes flushing at 30 to 50 mg and above: reddening of the face, arms, and chest, along with burning or tingling. At pharmacologic doses of 1,000 to 3,000 mg per day it can cause more serious effects including impaired glucose tolerance, gastrointestinal effects, and liver toxicity when taken over months or years [4].

Nicotinamide does not carry the same flushing profile, which is why NMN trials have not reported flushing [4]. The high-dose nicotinic acid warnings do not transfer directly to NMN. That is a point in NMN's favour and worth stating plainly.

NMN Regulatory Status in India: What the FSSAI Notice Says

Here is where the Indian context diverges sharply from what an American or Japanese article would tell you.

NMN is not listed as a permitted ingredient under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food, and Novel Food) Regulations, 2016 [3].

In a notice dated 24 July 2026, the FSSAI described NMN as an unapproved ingredient. The notice went to two Gujarat-based companies and was copied to e-commerce platforms, which were told to de-list the product concerned. Failure to comply may attract penalties under the Food Safety and Standards Act [3].

Companies can seek approval through the FSSAI's non-specified food and food ingredients route. As of the list published on the FSSAI website on 3 June, no NMN ingredient or product had been approved. Two applications were under process and six had been rejected [3].

This is a regulatory status, not a safety verdict. The FSSAI has not stated that NMN is harmful. It has stated that NMN has not completed the approval pathway that Indian law requires before an ingredient can be sold in a supplement.

For a reader in India, the practical implication is worth being direct about. Products containing NMN are widely listed on Indian e-commerce platforms despite this, and buying one means buying a product whose ingredient has not been cleared by the national food regulator.

Questions Worth Asking Before Long-Term Use

Anyone considering extended NMN use has a few reasonable things to raise with a doctor.

Whether existing medications interact. The trials recruited healthy adults, so medication interactions are largely unstudied.

Whether a personal or family history of cancer changes the calculus. Some researchers have raised theoretical questions about NAD+ boosting in the context of cancer, though human clinical evidence has not established an association with increased cancer risk [7]. This is a question for an oncologist, not an article.

What the baseline bloodwork looks like. Liver and kidney function tests before starting give a reference point that makes any later change interpretable.

Whether the product is what it claims to be. Third-party testing and a certificate of analysis are the only practical way a buyer can verify content and purity.

What This Means If You Are Deciding

The evidence supports a specific, limited statement: at doses up to 1,250 mg daily, over periods up to 12 weeks, in healthy adults, NMN has been well tolerated in published trials with no serious adverse events reported [1][2][5][6].

Anything beyond that window is extrapolation. It may well turn out to be fine. It has not been demonstrated.

For a reader in India there is a second, more immediate consideration that sits upstream of the science. Whatever the trials show, NMN has not been approved for supplement use by the FSSAI, and no application had cleared as of June 2026 [3].

Someone weighing this up is really answering two questions. Is the safety evidence strong enough for my situation, given my medications and history? And am I comfortable with the regulatory position as it stands in India today? A doctor can help with the first. The second is a personal call, and it is a reasonable one to sit with.

For readers who want to understand the underlying biology before making that decision, NAD+ decline and its symptoms in Indians covers what actually drops with age. What NMN is and whether it works examines the efficacy evidence, which is a separate question from safety. How long you should take supplements for is worth reading alongside this one, since duration is the crux here. For the wider category, longevity and healthy ageing puts supplements next to the levers with stronger evidence behind them, and supplements and nutraceuticals for Indians covers how to read an Indian supplement label.

Readers comparing options across the NAD+ category may want to look at how NMN with resveratrol is labelled and tested, and at CoQ10 for heart and mitochondria, an ingredient with a longer regulatory and clinical track record in India. Checking the certificate of analysis and the FSSAI position on every ingredient is worth doing regardless of brand.

Frequently Asked Questions

How long have people safely taken NMN in studies?

The longest published human trial ran 12 weeks [2]. The others ran four weeks, eight weeks, and 60 days. No published study has followed people taking NMN for a year or more, so safety beyond roughly three months is untested rather than disproven.

Does NMN cause flushing like niacin?

The NMN trials have not reported flushing. Flushing is associated with nicotinic acid, a different form of vitamin B3 with a different toxicity profile from nicotinamide, which is what NMN converts to [4].

Is NMN legal to sell in India?

NMN is not currently an approved supplement ingredient under India's 2016 nutraceutical regulations. The FSSAI issued a notice on 24 July 2026 describing it as unapproved and instructed e-commerce platforms to de-list a product containing it. Approval can be sought through the non-specified food route, and as of 3 June 2026 no application had been approved [3].

What was the highest dose tested in a safety trial?

A randomised, double-blind, placebo-controlled trial gave 1,250 mg once daily to 31 healthy adults for four weeks and found no changes beyond normal physiological variation and no severe adverse events [5].

Are the NMN safety studies large enough to trust?

They are small. The four main safety trials enrolled 80, 36, 31, and 11 participants. Trials of this size can pick up common side effects but are not large enough to detect rare ones.

Should someone with a health condition take NMN long term?

The published trials recruited healthy adults, so there is little evidence on people with existing conditions or those taking medications. That makes it a question for a healthcare professional who knows the full medical history.

References

1. Yi, Lin, et al. "The Efficacy and Safety of β-Nicotinamide Mononucleotide (NMN) Supplementation in Healthy Middle-Aged Adults: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Dependent Clinical Trial." GeroScience, vol. 45, no. 1, Feb. 2023, pp. 29-43. PubMed, https://pubmed.ncbi.nlm.nih.gov/36482258/.

2. Katayoshi, Takeshi, et al. "Nicotinamide Adenine Dinucleotide Metabolism and Arterial Stiffness after Long-Term Nicotinamide Mononucleotide Supplementation: A Randomized, Double-Blind, Placebo-Controlled Trial." Scientific Reports, vol. 13, no. 2786, 16 Feb. 2023, https://www.nature.com/articles/s41598-023-29787-3.

3. Koe, Tingmin. "FSSAI Sends Notice Warning against the Use of NMN in Supplements." NutraIngredients, 3 Aug. 2026, https://www.nutraingredients.com/Article/2026/08/03/nmn-an-unapproved-ingredient-for-supplement-use-in-india-says-the-fssai/.

4. Office of Dietary Supplements. "Niacin: Fact Sheet for Health Professionals." National Institutes of Health, https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/.

5. Fukamizu, Yuichiro, et al. "Safety Evaluation of β-Nicotinamide Mononucleotide Oral Administration in Healthy Adult Men and Women." Scientific Reports, vol. 12, no. 14442, 24 Aug. 2022, https://www.nature.com/articles/s41598-022-18272-y.

6. Yamaguchi, Shintaro, et al. "Safety and Efficacy of Long-Term Nicotinamide Mononucleotide Supplementation on Metabolism, Sleep, and Nicotinamide Adenine Dinucleotide Biosynthesis in Healthy, Middle-Aged Japanese Men." Endocrine Journal, vol. 71, no. 2, 2024, pp. 153-169. PubMed, https://pubmed.ncbi.nlm.nih.gov/38191197/.

7. Song, Qin, et al. "The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: An Update." Advances in Nutrition, vol. 14, no. 6, Nov. 2023, pp. 1416-1435. PubMed, https://pubmed.ncbi.nlm.nih.gov/37619764/.

The information on this page is for educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before making changes to your supplement routine. Statements on this page have not been evaluated by the Food Safety and Standards Authority of India (FSSAI).